生物技术公司Coherus BioSciences宣布,其合作伙伴强生(Janssen)将向公司提供在研疗法Pasritamig。根据协议安排,Coherus BioSciences将作为该疗法1B期临床试验的申办方,负责试验的推进与执行。
生物技术公司Coherus BioSciences宣布,其合作伙伴强生(Janssen)将向公司提供在研疗法Pasritamig。根据协议安排,Coherus BioSciences将作为该疗法1B期临床试验的申办方,负责试验的推进与执行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.